Shanghai-Based Yaosu Technology Drives Organ Chip Adoption, Aims to Shape Domestic Regulatory Standards
Yaosu Technology, a Shanghai-based company specializing in microphysiological systems, has seen significant growth in it’s organ chip business. Teh company offers a product matrix covering tissue models including the liver, kidneys, lungs, and intestines, and has shipped over 10,000 sets of organ chips, doubling its output in just six months.
According to Xie Xin, new technologies thrive in innovative environments, and organ chips – requiring expertise at the intersection of medicine and industry - benefit from Shanghai’s robust ecosystem of biology, medicine, pharmacy, AI, computer vision, and a strong talent pool. Yaosu Technology is currently building its East China headquarters and R&D center in Fengxian Returned Town, with plans to establish an organ chip application hub for the Asia-Pacific region.
The increasing adoption of organ chips is being fueled by global regulatory shifts. Ye Sen highlighted the meaning of the FDA’s regulatory scientific modernization strategy, noting that all 20 of the world’s top multinational pharmaceutical companies are now utilizing organ chips for drug efficacy and safety evaluation during new drug advancement. Organ chips are increasingly being used alongside traditional animal experiments, with several new drug projects, screened using both methods, already approved for clinical trials. The growing number of Chinese original innovative drugs seeking international approval is driving demand for platforms capable of meeting “China-US dual reporting” requirements.
leveraging its industry-leading technologies and experience collaborating with international regulatory bodies like the FDA, Yaosu Technology is accelerating the global application of its products and contributing to the development of next-generation regulatory paradigms. The company is actively collaborating with the Municipal Health Commission and municipal Drug Management in Fengxian, with support from relevant departments, to develop China’s first organ chip technology review guide, modeled after international cooperation frameworks.
This initiative aims to establish standards for organ chip applications and potentially reshape the century-old paradigm of new drug research and development.
Source: Wenhui Daily, Ren Quan. Edited by Jin Yiling. Image provided by interviewee.